IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Accelerates Clinical Readouts, Supporting Near-Term Upside Potential
![]() |
Robust cash reserves and an active clinical-catalyst schedule through early September create a constructive near-term backdrop for the stock. Multiple pipeline updates and an expanding combination program underpin a positive operational narrative. |








